This is a 16-week study for subjects with a venous leg ulcer between the knee and ankle. This research is being done to determine the effectiveness of two dosing frequencies and two different concentrations of HP802-247, together with standard care, compared to placebo, plus standard care.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
228
One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
Placebo (Vehicle) consisting of: Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution
The Average Percent (%) Change From Baseline in the Target Wound Area in Each Treatment Group Over the Twelve-week Double-blind Treatment Period.
For each treatment group the area of each subject's target ulcer was measured on a weekly basis, for up to 12 weeks, or until wound closure, whichever occurred first, using a laser-based wound imaging system in conjunction with software to measure area. An average of the 12 measurements were assessed.
Time frame: Weekly, over the 12 week treatment period, or until wound closure, which ever occurred first
Kaplan-Meier Probability of Non-Closure
This key secondary outcome was the days to wound closure based on a Kaplan-Meier survival analysis.
Time frame: 14 weeks - the final visit for one subject was delayed by two weeks
Percent of Change From Baseline in Target Wound Area at Each of the Twelve Double-blind Treatment Weeks.
For each treatment group the area of each subject's target ulcer was measured on a weekly basis, for up to 12 weeks, using a laser-based wound imaging system in conjunction with software to measure area.
Time frame: Weekly, over the 12 week treatment period, or until wound closure, which ever occurred first
Proportion of Subjects Achieving ≥ 50% Decrease in Target Wound Area From Baseline Through Week 13
The area of each subject's target wound was measured at each visit and the proportion of subjects with a decrease in area from baseline ≥ 50% was calculated for each treatment group.
Time frame: Over the 12 week treatment period or until the wound closed, which ever occurred first.
Percentage of Participants With Complete Wound Closure at Each Visit
Treatment groups were compared for the proportion of wounds closed at each weekly visit. For subjects who dropped from the study, their remaining visit values were imputed using LOCF.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of AZ College of Medicine
Tucson, Arizona, United States
Center for Clinical Research
Castro Valley, California, United States
ILD Consulting, Inc.
Encinitas, California, United States
Vascular Surgery Associates
Los Angeles, California, United States
UCSD Wound Treatment and Research Center
San Diego, California, United States
University of Miami
Miami, Florida, United States
Doctors Research Network
South Miami, Florida, United States
Robert J. Snyder
Tamarac, Florida, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Passavant Area Hospital
Jacksonville, Illinois, United States
...and 20 more locations
Time frame: Weekly, over the 12 week treatment period
Target Ulcer Pain Was Measured Using a Visual Analog Scale [Range: 0mm - 100mm]. Subjects Marked Their Pain Level on a 100 mm Horizontal Line, With a Short Vertical Line Across the Scale, 0 Denoting no Pain and 100mm the Maximum Pain.
Target ulcer pain was measured using a Visual Analog Scale \[Range: 0mm - 100mm\]. Subjects marked their pain level on a 100 mm horizontal line, with a short vertical line across the scale, 0 denoting no pain and 100mm the maximum pain. Each weekly measurement is reported as the average of all subjects scores at each week per treatment group.
Time frame: Weekly, over the 12 week treatment period
Median Time to Achieve Complete Wound Closure, Based on Based on a Kaplan-Meier Survival Analysis, Over the 12-Week Treatment Period From Baseline.
This key secondary outcome was the days to wound closure based on a Kaplan-Meier survival analysis.
Time frame: 14 weeks - the final visit for one subject was delayed by two weeks